Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with a primary focus in oncology and hematology, today announced the launch of the Company’s broad-based FUSILEV (levoleucovorin) marketing campaign directed towards oncologists, nurses, office practice managers and pharmacists. The recently launched campaign features a new FUSILEV.com website, health care professional educational tools and resources, digital and online campaign, and peer-to-peer live educational programs. In conjunction with the launch of this new marketing campaign, and in an effort to further increase our market penetration, Spectrum has made the strategic decision to dedicate additional existing sales resources to FUSILEV. Augmenting the Company’s dedicated FUSILEV sales force, all ZEVALIN® (ibritumomab tiuxetan) Injection for Intravenous Use representatives will now also promote FUSILEV. This strategy will leverage all existing health care professional relationships and effectively increase Spectrum’s FUSILEV dedicated sales resources by approximately 50% with no significant increase in operating expenses. “Physicians continue to increasingly use FUSILEV because of its purity, clinical profile, and supply reliability,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “Strong commercial support for FUSILEV has been rewarded by increased market penetration and sustained customer loyalty. We believe this campaign will continue to raise awareness of the FUSILEV brand as well as grow the folate analog market.” About FUSILEV® (levoleucovorin) FUSILEV, a folate analog, is approved as a ready-to-use solution (FUSILEV Injection), and as a freeze-dried powder (FUSILEV for Injection). FUSILEV is indicated for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. FUSILEV is also indicated for rescue after high-dose methotrexate therapy in osteosarcoma. FUSILEV is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. FUSILEV, under various trade names, is marketed outside the United States by Pfizer, Sanofi-Aventis, and Takeda.